GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
I

INVO Fertility IVF · USD

Health Care · US listing · 🇺🇸 United States

Compare

2.35

+9.81%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$6.8m

FY2016FY2025

Net income

−$23.3m

FY2016FY2025

Free cash flow

−$7.1m

FY2016FY2025

Shareholders' equity

$7.2m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$6.8m$6.5m$3.0m$822,196$4.2m$1.0m$1.5m$494,375$282,145$50,901
Gross profit$2.5m$2.9m$1.1m−$28,574$4.0m$948,526$1.3m$404,008$230,191$35,807
Research and development—$489,660$165,945$544,043$216,430$398,426————
Operating income−$5.8m−$8.1m−$7.1m−$10.8m−$5.4m−$5.5m−$1.8m−$2.6m−$640,421−$2.1m
Net income−$23.3m−$9.1m−$8.0m−$10.9m−$6.7m−$8.3m−$2.2m−$3.1m−$702,163−$2.1m
Diluted earnings per share-48.85-2,934.14-4,726.24-27,231.28-16,637.35-41,736.58-10,837.72-15,380.46-3,510.82-9.67

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$20.2m$46.4m$18.5m$3.7m$10.5m$10.9m$1.8m$777,347$266,413$286,226
Cash and short-term investments$2.1m$741,396$232,424$90,135$5.7m$10.1m$1.2m$212,243$25,759$152,404
Total liabilities$13.0m$33.7m$17.6m$4.7m$3.2m$5.2m$5.5m$3.5m$5.3m$4.9m
Debt$3.4m$9.9m$6.3m$2.3m$2.1m$775,024$457,467$395,591$342,610$352,610
Shareholders' equity$7.2m$12.7m$892,825−$977,612$7.3m$5.7m−$3.7m−$2.7m−$5.0m−$4.6m
Shares outstanding0m0m0m0m0m0m0m0m0m0m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−$7.0m−$3.0m−$4.8m−$6.6m−$6.0m−$4.8m$1.4m−$652,971−$181,270−$323,900
Capital spending−$43,412−$183,703−$444,726−$12,728−$454,649−$88,930−$64,843−$19,399—−$15,700
Free cash flow−$7.1m−$3.2m−$5.2m−$6.6m−$6.5m−$4.9m$1.3m−$672,370−$181,270−$339,600

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$2.2m$2.0m$1.6m$1.8m$1.9m$1.6m$1.7m$1.4m
Gross profit$617,100$727,826$536,860$629,345$770,051$592,256$728,547$444,686
Operating income−$1.3m−$5.4m$2.5m−$2.5m−$3.0m−$2.5m−$4.0m−$1.3m
Net income$888,740−$5.5m$2.0m−$2.6m−$5.3m−$17.4m−$3.6m−$1.6m
Diluted earnings per share0.34-2.144.21-5.54-11.07-36.45-1,168.87-526.02
Cash from operations−$1.0m−$1.0m—−$1.0m−$1.0m−$3.0m——
Total assets$25.8m$24.7m$20.2m$18.8m$19.3m$31.7m$46.4m$17.0m
Cash and short-term investments$3.7m$4.9m—$355,891$549,181$840,407$741,396$471,591
Debt$2.0m$2.2m$744,725$2.2m$5.1m$6.7m$7.7m$3.1m
Shareholders' equity$16.5m$15.0m$7.2m$5.8m$2.6m$3.3m$12.7m−$23,316

Growth per year

Compound annual rate

3 years5 years10 years
Revenue102.6%45.8%89.1%
Operating income-18.6%1.2%25.7%
Net income28.9%22.8%16.7%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin40.4%37.5%51.0%54.3%
Operating margin-104.0%-184.8%-190.6%-204.1%
Net margin-242.4%-298.2%-296.0%-320.9%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-0.3-0.5-0.5-0.4-3.1-1.1-24.9-34.1-55.2-45252.6
Price to sales1.10.71.45.05.09.036.5212.4137.3—

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return-99%-38%-77%-84%26%-83%-53%161%-47%-51%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 4-to-1 reverse split · 30 Oct 2026
  • 5-to-1 reverse split · 27 Mar 2026
  • 8-to-1 reverse split · 28 Nov 2025
  • 3-to-1 reverse split · 21 Jul 2025
  • 12-to-1 reverse split · 18 Mar 2025
  • 20-to-1 reverse split · 28 Jul 2023

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.